Chimerix

CMX001

CMX001 combines Chimerix’s Lipid-Antiviral-Conjugate Technology with cidofovir, an approved antiviral agent, with the aim of creating a well-tolerated and highly potent new chemical entity with broad-spectrum antiviral activity.  We believe that if we can successfully develop a product with increased efficacy and reduced toxicities we can provide a powerful new option for patients and their physicians that may dramatically change antiviral treatment, particularly among immunocompromised patients.  In clinical testing to date, CMX001 has shown oral bioavailability in humans and has demonstrated a positive safety profile.

We are currently conducting clinical trials of CMX001 for the treatment of dsDNA viruses in immunocompromised transplant patients. 

CMX001 is a mimic of a naturally occurring lipid, lysolecithin, formed by linking a lipid, 3-hexadecyloxy-1-propanol, to the phosphonate group of cidofovir. CMX001 is designed to readily cross the intestinal wall and penetrate target cells before being cleaved to free the antiviral, cidofovir.  Cidofovir is phosphorylated by host cell nucleoside kinases to form the active antiviral agent cidofovir diphosphate.